Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tranexamic acid for cerebral amyloid angiopathy with recent symptomatic intracranial bleeding
ACTRN12624001477516Phase 2Recruiting
- Sponsor
- Alfred Health
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cerebral amyloid angiopathy (CAA) comparing Tranexamic acid with Placebo (2 arms). Primary endpoints: Feasibility and Safety. Started Jun 2025; status: recruiting.
02
Drugs
tranexamic acid
03
Conditions
cerebral amyloid angiopathy (CAA)
Beyond the preview
Go deeper on ACTRN12624001477516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12624001477516.